← Back to searchRecruitingRecruiting
Electrical Stimulation for the Treatment of Glaucoma
NCT05626491 · Stanford University
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
Evaluate the Safety and Efficacy of Repetitive, Transorbital Alternating Current Stimulation (rtACS) for the Treatment of Glaucoma
About this study
The overall aim of this study is to see whether long-term electrical stimulation with a home-stimulation device works well and is safe for the treatment of open-angle glaucoma. Open-Angle Glaucoma is a disease where the nerves in the back of your eye die off faster than expected regardless of your eye pressure.
Eligibility criteria
Inclusion Criteria:
1. Participant must be at least 18.
2. Participant must has the ability to comply with the requirements of the study and complete the schedule of events (SOE).
3. Participant's clinical diagnosis must be consistent with glaucoma characterized by the following features: Mean deviation (MD) worse than -3 on Humphrey Visual Field 24-2 testing. Reliable visual field measures, fixation losses do not exceed 20% and false positives do not exceed 20%.
4. Visual Field Index between 10 and 90%
5. Corrected visual acuity ≥ 1.00 (logMAR), 20/200 (Snellen), 0.10 (decimal)
6. In the opinion of the investigator the participant's eye pressure must be clinically stable.
7. If a participant has two eyes meeting study criteria, the worse eye as determined by mean deviation. If both eyes qualify and have the same MD, the patient may choose which eye they are willing to enter, or else a randomization procedure will assign one eye to the study.
8. Participant must understand and sign the informed consent. If the participant's vision is impaired to the point where he/she cannot read the informed consent document, the document will be read to the participant in its entirety.
Exclusion Criteria:
1. Participant is unable to comply with study procedures or follow-up visits.
2. Participant has a history of ocular herpes zoster.
3. Participant has pathological nystagmus
4. Participant has evidence of visually significant retinopathy including but not limited to Diabetic retinopathy or retinitis pigmentosa.
5. Participant has evidence of corneal opacification or lack of optical clarity.
6. Participant has uveitis or other ocular inflammatory disease.
7. Participant has any electric or electronic implants such as a pacemaker.
8. Participant has acute conjunctivitis.
9. Participant has acute autoimmune disease.
10. Participant is currently participating in or has within the last 3 months participated in any other clinical trial of a drug by ocular (if in the study eye) or systemic administration.
11. Participant is pregnant or lactating.
12. Participant has, in the opinion of the investigator, any physical or mental condition that would increase the risk of participation in the study or may interfere with the study procedures, evaluations and outcome assessments. Including but not limited to all forms of dementia.
13. Unresected brain tumors
14. Implanted intracranial magnetic metals (metallic implants in the head / skull such as clamps, coils, ventriculo-peritoneal shunts, endoprostheses, etc.), which are not MRI-compatible. Note: metallic dental implants and titanium screws or plates are acceptable
15. Patients with any skin damage.
16. Children and comatose patients.
17. Patients with history of epileptic seizure within the last 10 years.
18. Patients with uncontrolled systemic hypertension or uncontrolled diabetes.
19. Self-reported alcohol or illicit drug addictions within the last 12 months.
20. Participant is not able to travel, to comply with the requirements of the study or not willing to complete the schedule of events (SOE) and/or unable to confirm follow-up participation
21. Prior participation in a vision training/stimulation study in the last 12 months
Study design
Enrollment target: 45 participants
Allocation: randomized
Masking: double
Age groups: adult, older_adult
Timeline
Starts: 2023-02-28
Estimated completion: 2025-12
Last updated: 2024-12-04
Interventions
Device: Repetitive, Transorbital Alternating Current Stimulation (rtACS)Device: Sham Repetitive, Transorbital Alternating Current Stimulation (rtACS)
Primary outcomes
- • Change from baseline in visual field assessed by Humphrey Visual Field Index (VFI). (Baseline through 6 months)
Sponsor
Stanford University · other
With: NYU Langone Health, Otto-von-Guericke University Magdeburg, Wills Eye
Contacts & investigators
InvestigatorJeffrey L Goldberg, MD PhD · principal_investigator, Stanford University
InvestigatorBernhard Sable, PhD · principal_investigator, Otto-von-Guericke University Magdeburg
InvestigatorJoeseph F Panarelli, MD · principal_investigator, NYU- Langone
All locations (4)
Byers Eye InstituteRecruiting
Palo Alto, California, United States
NYU- LangoneRecruiting
New York, New York, United States
Wills Eye HospitalRecruiting
Philadelphia, Pennsylvania, United States
Otto-von-Guericke UniversityRecruiting
Magdeburg, Germany